

Heterogeneity of Cholinergic Denervation in Parkinson

Journal of Cerebral Blood Flow and Metabolism

32, 1609-1617

DOI: [10.1038/jcbfm.2012.60](https://doi.org/10.1038/jcbfm.2012.60)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The neurobiology and neural circuitry of cognitive changes in Parkinson's disease revealed by functional neuroimaging. <i>Movement Disorders</i> , 2012, 27, 1484-1492.	2.2	32
2	Cholinergic Dysfunction in Parkinson's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2013, 13, 377.	2.0	193
3	Imaging: What can it tell us about parkinsonian gait?. <i>Movement Disorders</i> , 2013, 28, 1492-1500.	2.2	76
4	Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease. <i>Brain</i> , 2013, 136, 3282-3289.	3.7	140
5	In vivo neurochemical imaging of olfactory dysfunction in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2013, 120, 571-576.	1.4	40
6	Gender differences in cholinergic and dopaminergic deficits in Parkinson disease. <i>Journal of Neural Transmission</i> , 2013, 120, 1421-1424.	1.4	16
7	Neuroimaging of brain changes associated with cognitive impairment in Parkinson's disease. <i>Journal of Neuropsychology</i> , 2013, 7, 225-240.	0.6	28
8	Cortical control of saccades in Parkinson disease and essential tremor. <i>Journal of Neural Transmission</i> , 2013, 120, 145-156.	1.4	11
9	White-Matter Changes Correlate with Cognitive Functioning in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2013, 4, 37.	1.1	53
10	Pedunculopontine Cholinergic Cell Loss in Hallucinating Parkinson Disease Patients but Not in Dementia With Lewy Bodies Patients. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 1162-1170.	0.9	38
11	Modeling Fall Propensity in Parkinson's Disease: Deficits in the Attentional Control of Complex Movements in Rats with Cortical-Cholinergic and Striatal Dopaminergic Deafferentation. <i>Journal of Neuroscience</i> , 2013, 33, 16522-16539.	1.7	63
12	Gait speed in Parkinson disease correlates with cholinergic degeneration. <i>Neurology</i> , 2013, 81, 1611-1616.	1.5	185
14	Imaging and behavior in Parkinson's disease: functional imaging. , 0, , 89-96.		0
15	Nicotinic Acetylcholine Receptor Density in Cognitively Intact Subjects at an Early Stage of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 213.	1.7	21
16	Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1394-1398.	1.1	71
17	In Vivo Imaging of Human Acetylcholinesterase Density in Peripheral Organs Using ¹¹ C-Donepezil: Dosimetry, Biodistribution, and Kinetic Analyses. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1818-1824.	2.8	40
18	Decreased ipsilateral [¹²³ I]iododexetimide binding to cortical muscarinic receptors in unilaterally 6-hydroxydopamine lesioned rats. <i>Nuclear Medicine and Biology</i> , 2014, 41, 90-95.	0.3	7
19	Reassessment of the Role of the Central Cholinergic System. <i>Journal of Molecular Neuroscience</i> , 2014, 53, 352-358.	1.1	9

#	ARTICLE	IF	CITATIONS
20	The neurobiological basis of cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 634-650.	2.2	282
21	The pathomechanisms underlying Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 199-215.	1.4	61
22	Extra-nigral pathological conditions are common in Parkinson's disease with freezing of gait: An <i>in vivo</i> positron emission tomography study. <i>Movement Disorders</i> , 2014, 29, 1118-1124.	2.2	101
23	Nicotinic $\alpha 4\beta 2$ acetylcholine receptors and cognitive function in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2014, 130, 164-171.	1.0	21
24	Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: Cognitive and neurochemical correlates. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1076-1080.	1.1	60
25	Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function. <i>Experimental Neurology</i> , 2014, 257, 120-129.	2.0	90
26	Parkinson's disease: what role do pedunculopontine cholinergic neurons play?. <i>Future Neurology</i> , 2014, 9, 5-8.	0.9	5
27	Dopaminergic therapy affects learning and impulsivity in Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 833-843.	1.7	19
28	Structural MRI Correlates of Episodic Memory Processes in Parkinson's Disease Without Mild Cognitive Impairment. <i>Journal of Parkinson's Disease</i> , 2015, 5, 971-981.	1.5	15
29	Association between Community Ambulation Walking Patterns and Cognitive Function in Patients with Parkinson's Disease: Further Insights into Motor-Cognitive Links. <i>Parkinson's Disease</i> , 2015, 2015, 1-11.	0.6	16
30	Frequency of Cholinergic and Caudate Nucleus Dopaminergic Deficits Across the Predemented Cognitive Spectrum of Parkinson Disease and Evidence of Interaction Effects. <i>JAMA Neurology</i> , 2015, 72, 194.	4.5	121
31	<i>LRRK2</i> genetic variants in parkinsonism. <i>Movement Disorders</i> , 2015, 30, 273-278.	2.2	42
32	Clinical markers for identifying cholinergic deficits in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 269-273.	2.2	54
33	Cognitive impairment in Parkinson's disease. <i>Postgraduate Medical Journal</i> , 2015, 91, 212-220.	0.9	50
34	Impact of image-based motion correction on dopamine D3/D2 receptor occupancy: comparison of groupwise and frame-by-frame registration approaches. <i>EJNMMI Physics</i> , 2015, 2, 15.	1.3	11
35	Non-exercise physical activity attenuates motor symptoms in Parkinson disease independent from nigrostriatal degeneration. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1227-1231.	1.1	18
36	Preclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson's Disease. <i>Neuropsychology Review</i> , 2015, 25, 371-383.	2.5	19
37	Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 49, 157-170.	2.9	31

#	ARTICLE	IF	CITATIONS
38	Neural substrates of levodopa-responsive gait disorders and freezing in advanced Parkinson's disease: A kinesthetic imagery approach. <i>Human Brain Mapping</i> , 2015, 36, 959-980.	1.9	30
39	Attentional Control of Gait and Falls: Is Cholinergic Dysfunction a Common Substrate in the Elderly and Parkinson's Disease?. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 104.	1.7	58
40	Compensatory neural mechanisms in cognitively unimpaired Parkinson disease. <i>Annals of Neurology</i> , 2016, 79, 448-463.	2.8	62
41	Striatal and Cortical Amyloidopathy and Cognition in Parkinson's Disease. <i>Movement Disorders</i> , 2016, 31, 111-117.	2.2	52
42	Physiology of freezing of gait. <i>Annals of Neurology</i> , 2016, 80, 644-659.	2.8	160
43	Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline. <i>Neuron</i> , 2016, 91, 1199-1218.	3.8	523
44	Brainstem control of locomotion and muscle tone with special reference to the role of the mesopontine tegmentum and medullary reticulospinal systems. <i>Journal of Neural Transmission</i> , 2016, 123, 695-729.	1.4	157
45	Biomarkers for dementia and mild cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 861-881.	2.2	118
46	Postural instability and falls in Parkinson's disease. <i>Reviews in the Neurosciences</i> , 2016, 27, 549-555.	1.4	44
47	Neural Control of Walking in People with Parkinsonism. <i>Physiology</i> , 2016, 31, 95-107.	1.6	112
48	Neuroimaging and clinical predictors of fatigue in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2016, 23, 45-49.	1.1	33
49	Cognitive decline in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 217-231.	4.9	705
50	Thalamic cholinergic innervation makes a specific bottom-up contribution to signal detection: Evidence from Parkinson's disease patients with defined cholinergic losses. <i>NeuroImage</i> , 2017, 149, 295-304.	2.1	34
51	Motor dysfunction and alterations in glutathione concentration, cholinesterase activity, and BDNF expression in substantia nigra pars compacta in rats with pedunculopontine lesion. <i>Neuroscience</i> , 2017, 348, 83-97.	1.1	9
52	Imaging in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 233-274.	0.9	21
53	Characterizing Cognitive Impairment in Parkinson's Disease. <i>Seminars in Neurology</i> , 2017, 37, 167-175.	0.5	6
54	PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 90.	2.0	20
55	Color discrimination errors associate with axial motor impairments in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 864-869.	0.8	5

#	ARTICLE	IF	CITATIONS
56	Mentally stimulating activities associate with better cognitive performance in Parkinson disease. <i>Journal of Neural Transmission</i> , 2017, 124, 1205-1212.	1.4	5
57	The fate of the brain cholinergic neurons in neurodegenerative diseases. <i>Brain Research</i> , 2017, 1670, 173-184.	1.1	102
58	Cognition in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 133, 557-583.	0.9	51
59	Cholinergic Oculomotor Nucleus Activity Is Induced by REM Sleep Deprivation Negatively Impacting on Cognition. <i>Molecular Neurobiology</i> , 2017, 54, 5721-5729.	1.9	5
60	Deletion of the vesicular acetylcholine transporter from pedunculo pontine/laterodorsal tegmental neurons modifies gait. <i>Journal of Neurochemistry</i> , 2017, 140, 787-798.	2.1	34
61	The Cholinergic System Modulates Memory and Hippocampal Plasticity via Its Interactions with Non-Neuronal Cells. <i>Frontiers in Immunology</i> , 2017, 8, 1489.	2.2	173
62	A model-based quantification of action control deficits in Parkinson's disease. <i>Neuropsychologia</i> , 2018, 111, 26-35.	0.7	8
63	Recent Advances in Cholinergic Imaging and Cognitive Decline—Revisiting the Cholinergic Hypothesis of Dementia. <i>Current Geriatrics Reports</i> , 2018, 7, 1-11.	1.1	75
64	In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease. <i>Brain</i> , 2018, 141, 165-176.	3.7	135
65	Parkinson disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 159, 173-193.	1.0	22
66	Targeting the pedunculo pontine nucleus in Parkinson's disease: Time to go back to the drawing board. <i>Movement Disorders</i> , 2018, 33, 1871-1875.	2.2	16
67	Regional vesicular acetylcholine transporter distribution in human brain: A [¹⁸ F]fluoroethoxybenzovesamicol positron emission tomography study. <i>Journal of Comparative Neurology</i> , 2018, 526, 2884-2897.	0.9	45
68	Molecular Imaging of the Cholinergic System in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2018, 141, 211-250.	0.9	40
69	Brain imaging of locomotion in neurological conditions. <i>Neurophysiologie Clinique</i> , 2018, 48, 337-359.	1.0	40
70	Cognitive deficits in Parkinson's disease: current perspectives. <i>Journal of Parkinsonism and Restless Legs Syndrome</i> , 2018, Volume 8, 1-11.	0.8	2
71	Salivary biomarkers for the diagnosis and monitoring of neurological diseases. <i>Biomedical Journal</i> , 2018, 41, 63-87.	1.4	122
72	In Vivo Positron Emission Tomography of Extrastriatal Non-Dopaminergic Pathology in Parkinson Disease. <i>Contemporary Clinical Neuroscience</i> , 2018, , 143-170.	0.3	1
73	Dopamine-related dissociation of cortical and subcortical brain activations in cognitively unimpaired Parkinson's disease patients OFF and ON medications. <i>Neuropsychologia</i> , 2018, 119, 24-33.	0.7	12

#	ARTICLE	IF	CITATIONS
74	Model-based and Model-free Machine Learning Techniques for Diagnostic Prediction and Classification of Clinical Outcomes in Parkinson's Disease. Scientific Reports, 2018, 8, 7129.	1.6	95
75	Imaging Markers of Progression in Parkinson's Disease. Movement Disorders Clinical Practice, 2018, 5, 586-596.	0.8	23
76	The Neuroimaging of Brain Diseases. Contemporary Clinical Neuroscience, 2018, , .	0.3	1
77	Quantification of brain cholinergic denervation in dementia with Lewy bodies using PET imaging with [18F]-FEOBV. Molecular Psychiatry, 2019, 24, 322-327.	4.1	37
78	Lower volume, more impairment: reduced cholinergic basal forebrain grey matter density is associated with impaired cognition in Parkinson disease. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1251-1256.	0.9	40
79	Low Vitamin B12 and Parkinson Disease. Mayo Clinic Proceedings, 2019, 94, 757-762.	1.4	15
80	Alterations of Sleep and Sleep Oscillations in the Hemiparkinsonian Rat. Frontiers in Neuroscience, 2019, 13, 148.	1.4	11
81	Cholinergic system changes of falls and freezing of gait in Parkinson's disease. Annals of Neurology, 2019, 85, 538-549.	2.8	115
82	Overview of the cholinergic contribution to gait, balance and falls in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 63, 20-30.	1.1	49
83	How Cognition and Motivation "Freeze" the Motor Behavior in Parkinson's Disease. Frontiers in Neuroscience, 2019, 13, 1302.	1.4	9
84	The pedunclopontine nucleus and Parkinson's disease. Neurobiology of Disease, 2019, 128, 3-8.	2.1	25
85	Dichotomy between motor and cognitive functions of midbrain cholinergic neurons. Neurobiology of Disease, 2019, 128, 59-66.	2.1	14
86	Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson's disease. Psychopharmacology, 2019, 236, 1701-1715.	1.5	8
87	Cholinergic double duty: cue detection and attentional control. Current Opinion in Psychology, 2019, 29, 102-107.	2.5	45
88	Multimodal magnetic resonance imaging investigation of basal forebrain damage and cognitive deficits in Parkinson's disease. Movement Disorders, 2019, 34, 516-525.	2.2	42
89	The cortical cholinergic system contributes to the top-down control of distraction: Evidence from patients with Parkinson's disease. NeuroImage, 2019, 190, 107-117.	2.1	33
90	Compensatory dopaminergic-cholinergic interactions in conflict processing: Evidence from patients with Parkinson's disease. NeuroImage, 2019, 190, 94-106.	2.1	17
91	Short-afferent inhibition and cognitive impairment in Parkinson's disease: A quantitative review and challenges. Neuroscience Letters, 2020, 719, 133679.	1.0	11

#	ARTICLE	IF	CITATIONS
92	Therapeutic approaches to cholinergic deficiency in Lewy body diseases. Expert Review of Neurotherapeutics, 2020, 20, 41-53.	1.4	6
93	Cholinergic denervation in patients with idiopathic rapid eye movement sleep behaviour disorder. European Journal of Neurology, 2020, 27, 644-652.	1.7	30
94	Apathy rating scores and β -amyloidopathy in patients with Parkinson disease at risk for cognitive decline. Neurology, 2020, 94, e376-e383.	1.5	20
95	Gait variability is linked to the atrophy of the Nucleus Basalis of Meynert and is resistant to STN DBS in Parkinson's disease. Neurobiology of Disease, 2020, 146, 105134.	2.1	18
96	Impaired metabolic brain networks associated with neurotransmission systems in the α -synuclein spectrum. Parkinsonism and Related Disorders, 2020, 81, 113-122.	1.1	16
97	Sleep Deprivation and Neurological Disorders. BioMed Research International, 2020, 2020, 1-19.	0.9	88
98	Study protocol of the Dutch PARKinson Cohort (DUPARC): a prospective, observational study of de novo Parkinson's disease patients for the identification and validation of biomarkers for Parkinson's disease subtypes, progression and pathophysiology. BMC Neurology, 2020, 20, 245.	0.8	17
99	Topography of Cholinergic Changes in Dementia With Lewy Bodies and Key Neural Network Hubs. Journal of Neuropsychiatry and Clinical Neurosciences, 2020, 32, 370-375.	0.9	20
100	Complex Movement Control in a Rat Model of Parkinsonian Falls: Bidirectional Control by Striatal Cholinergic Interneurons. Journal of Neuroscience, 2020, 40, 6049-6067.	1.7	18
101	Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease. Neurobiology of Disease, 2020, 139, 104831.	2.1	49
102	What's wrong with the striatal cholinergic interneurons in Parkinson's disease? Focus on intrinsic excitability. European Journal of Neuroscience, 2021, 53, 2100-2116.	1.2	17
103	Cholinergic nucleus 4 atrophy and gait impairment in Parkinson's disease. Journal of Neurology, 2021, 268, 95-101.	1.8	11
104	Prodromal local sleep disorders in a rat model of Parkinson's disease cholinopathy, hemiparkinsonism and hemiparkinsonism with cholinopathy. Behavioural Brain Research, 2021, 397, 112957.	1.2	6
105	Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease. Movement Disorders, 2021, 36, 642-650.	2.2	41
106	Nucleus basalis of Meynert degeneration predicts cognitive impairment in Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 179, 189-205.	1.0	12
107	Lewy Body Disease. , 2021, , 18-41.		0
108	Delayed Hemiparkinsonism Associated with Kernohan's Notch in a Patient with a Ruptured Arteriovenous Malformation. Internal Medicine, 2021, 60, 309-313.	0.3	4
109	Make a Left Turn: Cortico-Striatal Circuitry Mediating the Attentional Control of Complex Movements. Movement Disorders, 2021, 36, 535-546.	2.2	10

#	ARTICLE	IF	CITATIONS
110	Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2021, 268, 4796-4808.	1.8	3
111	Aerobic Exercise Combined With Transcranial Direct Current Stimulation Over the Prefrontal Cortex in Parkinson Disease: Effects on Cortical Activity, Gait, and Cognition. <i>Neurorehabilitation and Neural Repair</i> , 2021, 35, 717-728.	1.4	20
112	$\alpha 4\beta 2$ Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease [*] Disorders. <i>Annals of Neurology</i> , 2021, 90, 130-142.	2.8	9
113	Mechanisms of Antiparkinsonian Anticholinergic Therapy Revisited. <i>Neuroscience</i> , 2021, 467, 201-217.	1.1	12
114	The Cholinergic Brain in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1012-1026.	0.8	42
115	Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9290.	1.8	65
116	Normal cognition in Parkinson's disease may involve hippocampal cholinergic compensation: An exploratory PET imaging study with [18F]-FEOBV. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 162-166.	1.1	16
117	Quantitative EEG and cholinergic basal forebrain atrophy in Parkinson's disease and mild cognitive impairment. <i>Neurobiology of Aging</i> , 2021, 106, 37-44.	1.5	10
118	Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 611-621.	2.2	25
119	Parkinson Dementia: PET Findings. , 2014, , 359-372.		2
120	Molecular imaging as a guide for the treatment of central nervous system disorders. <i>Dialogues in Clinical Neuroscience</i> , 2013, 15, 315-328.	1.8	18
122	The Practical Pharmacology of Donepezil. , 2016, , 27-33.		0
124	Lewy Body Disease. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2019, , 298-321.	0.1	0
126	Cognitive Enhancers as a Means to Reduce Falls in Older Adults. , 2020, , 323-341.		1
131	Varenicline for the treatment of postural and gait dysfunction in Parkinson's disease (PD). <i>Neurology: Clinical Practice</i> , 2021, 11, 10.1212/CPJ.0000000000000958.	0.8	4
132	Altered Cholinergic Innervation in De Novo Parkinson's Disease with and Without Cognitive Impairment. <i>Movement Disorders</i> , 2022, 37, 713-723.	2.2	27
133	Cholinergic systems, attentional-motor integration, and cognitive control in Parkinson's disease. <i>Progress in Brain Research</i> , 2022, 269, 345-371.	0.9	8
134	Cognition and serotonin in Parkinson's disease. <i>Progress in Brain Research</i> , 2022, 269, 373-403.	0.9	8

#	ARTICLE	IF	CITATIONS
135	Cerebral topography of vesicular cholinergic transporter changes in neurologically intact adults: A [18F]FEOBV PET study. <i>Aging Brain</i> , 2022, 2, 100039.	0.7	15
136	Mapping Actuarial Criteria for Parkinson's Disease-Mild Cognitive Impairment onto Data-Driven Cognitive Phenotypes. <i>Brain Sciences</i> , 2022, 12, 54.	1.1	4
137	Free-water imaging of the cholinergic basal forebrain and pedunclopontine nucleus in Parkinson's disease. <i>Brain</i> , 2023, 146, 1053-1064.	3.7	7
138	Cholinergic brain network deficits associated with vestibular sensory conflict deficits in Parkinson's disease: correlation with postural and gait deficits. <i>Journal of Neural Transmission</i> , 2022, 129, 1001-1009.	1.4	8
139	Inconsistencies in atlas-based volumetric measures of the human nucleus basalis of Meynert: A need for high-resolution alternatives. <i>NeuroImage</i> , 2022, 259, 119421.	2.1	9
140	Decreased vestibular efficacy contributes to abnormal balance in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2022, 440, 120357.	0.3	4
141	The effect of galvanic vestibular stimulation on postural balance in Parkinson's disease: A systematic review and meta-analysis. <i>Journal of the Neurological Sciences</i> , 2022, 442, 120414.	0.3	3
142	Identification of cholinergic centro-cingulate topography as main contributor to cognitive functioning in Parkinson's disease: Results from a data-driven approach. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	2
143	Mapping Cholinergic Synaptic Loss in Parkinson's Disease: An [18F]FEOBV PET Case-Control Study. <i>Journal of Parkinson's Disease</i> , 2022, 12, 2493-2506.	1.5	7
144	Atrophy of the Cholinergic Basal Forebrain can Detect Presynaptic Cholinergic Loss in Parkinson's Disease. <i>Annals of Neurology</i> , 2023, 93, 991-998.	2.8	5
145	Noradrenergic and cholinergic systems take centre stage in neuropsychiatric diseases of ageing. <i>Neuroscience and Biobehavioral Reviews</i> , 2023, 149, 105167.	2.9	8